|
Volumn 42, Issue 6, 1978, Pages 2546-2552
|
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5‐fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial
a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
FLUOROURACIL;
ADVERSE DRUG REACTION;
BLOOD AND HEMOPOIETIC SYSTEM;
BONE MARROW DEPRESSION;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CLINICAL TRIAL;
CONTROLLED STUDY;
DIGESTIVE SYSTEM;
DRUG COMPARISON;
GASTROINTESTINAL SYMPTOM;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MALE GENITAL SYSTEM;
METASTASIS;
ORAL DRUG ADMINISTRATION;
PROSTATE CANCER;
RANDOMIZED CONTROLLED TRIAL;
THERAPY;
ADENOCARCINOMA;
AGED;
BONE MARROW;
CLINICAL TRIALS;
CYCLOPHOSPHAMIDE;
DIGESTIVE SYSTEM;
DOXORUBICIN;
DRUG THERAPY, COMBINATION;
FLUOROURACIL;
HUMANS;
MALE;
MIDDLE AGED;
NEOPLASM METASTASIS;
PROSTATIC NEOPLASMS;
|
EID: 0018241866
PISSN: 0008543X
EISSN: 10970142
Source Type: Journal
DOI: 10.1002/1097-0142(197812)42:6<2546::AID-CNCR2820420607>3.0.CO;2-C Document Type: Article |
Times cited : (29)
|
References (8)
|